In future work, it will be important to screen and identify USP36 specific inhibitors that suppress USP36 activity in cancer cells and that will consequently inhibit PrimPol-dependent repriming and sensitize ovarian cancer to therapeutic drugs. This evidence concerns the gene USP36 and cancer.